Aditya Bardia, MD

Articles

Elacestrant vs Standard-of-Care in ER+/HER2- Advanced or Metastatic Breast Cancer (mBC) With ESR1 Mutation: Key Biomarkers and Clinical Subgroup Analyses From the Phase 3 EMERALD Trial

December 19th 2023

Aditya Bardia, MD, presents key data from biomarker and subgroup analyses of the EMERALD trial.

HR+/HER2- BC: Selecting a CDK4/6 Inhibitor in the Frontline Setting

July 4th 2022

Taking into account all 3 available CDK4/6 inhibitors in HR+/HER2- breast cancer, experts consider how they’d select frontline therapy in this setting.

CKD4/6 Inhibition in HR+/HER2- BC: Trial Data With Palbociclib

July 4th 2022

Panelists share insight on clinical trial data behind use of palbociclib in the frontline setting of HR+/HER2- breast cancer.

CKD4/6 Inhibition in HR+/HER2- BC: Trial Data With Abemaciclib and Ribociclib

June 27th 2022

Focusing on the frontline setting of HR+/HER2- breast cancer, panelists discuss clinical trial data with abemaciclib and ribociclib, respectively.

Frontline Treatment Strategies for HR+/HER2- Breast Cancer

June 27th 2022

Expert perspectives on the evolving treatment paradigm for patients receiving frontline therapy for HR+/HER2- breast cancer.

Role of ctDNA in the Neoadjuvant Setting of Breast Cancer

February 1st 2022

Expert perspectives on the value of circulating tumor DNA in the neoadjuvant setting of breast cancer management.

Applications of ctDNA Assessment in Metastatic Breast Cancer and Relapse

February 1st 2022

Aditya Bardia, MD, MPH, shares insight on how circulating tumor DNA is used in metastatic breast cancer and relapse detection.

Applications of ctDNA Assessment in Early Breast Cancer

January 25th 2022

Barry Rosen, MD, provides an overview of circulating tumor DNA’s role in early stage breast cancer detection and management.

An Overview of Minimal Residual Disease (MRD) Testing

January 25th 2022

Expert oncologist Aditya Bardia, MD, MPH, provides a broad overview of minimal residual disease testing across a number of tumor types and clinical settings.

Dr. Bardia on the Efficacy Results of the EMERALD Trial in ER+/HER2- Breast Cancer

December 10th 2021

Aditya Bardia, MD, MPH, discusses the efficacy results of the phase 3 EMERALD trial in estrogen receptor–positive, HER2-negative metastatic breast cancer.

Advances Treating HR+ Metastatic Breast Cancer

December 6th 2021

Various breast oncologists discuss the potential effect of treatment advances in hormone receptor-positive metastatic breast cancer.

Novel Therapies Under Investigation for HR+ MBC

December 6th 2021

An overview of key presentations from ESMO 2021 that continues studying the potential effect of novel-based treatment options for use in hormone receptor-positive metastatic breast cancer.

HR+ MBC: Genomic Testing and Treatment Guidance

November 29th 2021

A discussion on the current utilization of molecular testing in patients with HR-positive metastatic breast cancer, and recommendations for conducting liquid and tissue biopsies to help inform treatment decisions.

HR+ MBC: Ribociclib and Patient Quality of Life

November 17th 2021

Considerations for treating HR+ metastatic breast cancer with ribociclib plus endocrine therapy based on quality-of-life metrics demonstrated by a recent ESMO 2021 presentation.

Dr. Bardia on the Rationale for the AMEERA-5 Trial in ER+/HER2- Breast Cancer

June 24th 2021

Aditya Bardia, MD, MPH, discusses the rationale for the ongoing phase 3 AMEERA-5 trial in estrogen receptor–positive, HER2-negative breast cancer.

Dr. Bardia on Ongoing Research With Amcenestrant and Palbociclib in ER+/HER2- Advanced Breast Cancer

June 12th 2021

Aditya Bardia, MD, MPH, discusses ongoing research with amcenestrant and palbociclib in estrogen receptor–positive, HER2-negative advanced breast cancer.

Dr. Bardia on Efficacy With Atezolizumab Combos in Metastatic TNBC

March 2nd 2021

Aditya Bardia, MD, MPH, discusses efficacy with atezolizumab combinations in patients with metastatic triple-negative breast cancer.